A Phase 2 interventional study of Molnupiravir 200 mg and Molnupiravir 400 mg in SARS-CoV-2 Infection, COVID-19, sponsored by Ridgeback Biotherapeutics, LP. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.
Sponsored by Ridgeback Biotherapeutics, LP · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.
Among the 14 studies testing molnupiravir in COVID-19, this one is the 10th largest by enrollment, is one of 5 that started in 2020, is one of 2 in phase 2, and was the 2nd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
University of Liverpool · Sites in South Africa, United Kingdom
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2020; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 275 across the 14 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
Ridgeback Biotherapeutics, LP is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Ridgeback Biotherapeutics, LP has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies testing molnupiravir in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing molnupiravir in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of EIDD-2801 (molnupiravir) versus placebo as measured by SARS-CoV-2 viral RNA detection in symptomatic adult outpatients with COVID-19.
This was a phase IIa, double-blind, placebo-controlled, randomized trial, designed to compare the safety, tolerability, and antiviral activity of molnupiravir versus placebo as measured by SARS-CoV-2 viral RNA detection in symptomatic adult outpatients with COVID-19. The study was a multicenter trial that was conducted in the United States.
In this study, 204 participants were randomized and 202 received molnupiravir or placebo orally twice a day (BID) for 5 days. The study enrolled participants in 5 parts with each part evaluating molnupiravir doses of either 200 mg BID, 400 mg BID, or 800 mg BID. Doses were chosen based on emerging virology and safety data from this and ongoing studies. New dose groups were started after the selected dose had been studied for safety in a Phase 1 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant was eligible to participate if she was not pregnant or breastfeeding and at least one of the following conditions applied:
Male participants were eligible to participate if they agreed to the following during the intervention period and for at least 100 days after the last dose of study intervention:
PLUS either:
OR
Had to agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause [Appendix 2 of the study protocol]) as detailed below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Molnupiravir 200 mg, twice daily (BID) for 5 days
Drug: Molnupiravir 200 mg
Molnupiravir 400 mg, twice daily (BID) for 5 days
Drug: Molnupiravir 400 mg
Molnupiravir 800 mg, twice daily (BID) for 5 days
Drug: Molnupiravir 800 mg
Drug: Placebo (PBO)
Oral capsule of molnupiravir
Oral capsule of molnupiravir
Oral capsule of molnupiravir
placebo oral capsule
Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs
The number of participants until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification
Time frame: 28 days
Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs
The distribution of days until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification
Time frame: 28 days
Number of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment
1) any AEs leading to early discontinuation of blinded treatment (active or placebo), 2) study drug-related discontinuation of treatment, 3) new grade 3 or higher AEs (not already present at baseline), and 4) study drug-related new grade 3 or higher AEs.
Time frame: 28 days
Number of Participants With Any Adverse Events (AEs), Grade 2 or Higher
Measure the safety and tolerability of EIDD-2801 by estimating the occurrence of Grade 2 or higher AE and drug related AEs.
Time frame: 28 days
| Milestone | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Started | 23 | 64 | 55 | 62 |
| Number of subjects randomized not dosed | 0 | 2 | 0 | 0 |
| Number of subjects in the safety population | 23 | 62 | 55 | 62 |
| Number of subjects in the mitt population | 23 | 61 | 53 | 61 |
| Completed | 23 | 59 | 52 | 61 |
| Not completed | 0 | 5 | 3 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 |
| Withdrew: Randomized not dosed | 0 | 2 | 0 | 0 |
The number of participants until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification
| Participants | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Number (%) with response | 21 | 48 | 49 | 49 |
| Number (%) censored | 2 | 13 | 4 | 12 |
The distribution of days until first non-detectable SARS-CoV-2 in nasopharyngeal (NP) swabs will be estimated for each randomized arm (drug versus placebo), using Kaplan-Meier methods with a corresponding log-rank test. Non detectable defined as "a viral load below the limit of quantification
| Days | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs | 22.0 (15.0 to 28.0) | 27.0 (15.0 to 28.0) | 14.0 (13.0 to 14.0) | 15.0 (15.0 to 27.0) |
1) any AEs leading to early discontinuation of blinded treatment (active or placebo), 2) study drug-related discontinuation of treatment, 3) new grade 3 or higher AEs (not already present at baseline), and 4) study drug-related new grade 3 or higher AEs.
| Participants | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| AEs leading to early discontinuation of blinded treatment (active or placebo) | 0 | 1 | 1 | 1 |
| AEs leading to study drug-related discontinuation of treatment | 0 | 0 | 0 | 0 |
| new grade 3 or higher AEs (not already present at baseline) | 1 | 2 | 4 | 5 |
| study drug-related new grade 3 or higher AEs | 0 | 0 | 0 | 0 |
Measure the safety and tolerability of EIDD-2801 by estimating the occurrence of Grade 2 or higher AE and drug related AEs.
| Participants | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Any Adverse Events (AEs), Grade 2 or Higher | 5 | 7 | 6 | 9 |
Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Molnupiravir 200 mg | 0/23 (0%) | 0/23 (0%) | 4/23 (17.4%) |
| Molnupiravir 400 mg | 0/62 (0%) | 2/62 (3.2%) | 2/62 (3.2%) |
| Molnupiravir 800 mg | 0/55 (0%) | 1/55 (1.8%) | 1/55 (1.8%) |
| Placebo | 0/62 (0%) | 1/62 (1.6%) | 4/62 (6.5%) |
| Event | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/23 | 0/62 | 1/55 | 0/62 |
| Oxygen saturation decreasedInvestigations | 0/23 | 1/62 | 0/55 | 0/62 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/23 | 0/62 | 0/55 | 1/62 |
| Cerebrovascular accidentNervous system disorders | 0/23 | 1/62 | 0/55 | 0/62 |
| Event | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo |
|---|---|---|---|---|
| DizzinessNervous system disorders | 2/23 | 1/62 | 0/55 | 0/62 |
| InsomniaPsychiatric disorders | 2/23 | 1/62 | 1/55 | 4/62 |
| Age, Continuous(years) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 36.5 ± 15.34 | 42.4 ± 14.88 | 42.2 ± 14.36 | 39.7 ± 14.10 | 40.8 ± 14.57 |
| Sex: Female, Male(Participants) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 11 | 32 | 27 | 34 | 104 |
| Male | 12 | 30 | 28 | 28 | 98 |
| Ethnicity (NIH/OMB)(Participants) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 23 | 33 | 23 | 86 |
| Not Hispanic or Latino | 16 | 39 | 21 | 39 | 115 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Molnupiravir 200 mg | Molnupiravir 400 mg | Molnupiravir 800 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 1 | 2 | 6 |
| Black or African American | 3 | 3 | 3 | 2 | 11 |
| White | 17 | 56 | 49 | 54 | 176 |
| Other | 2 | 0 | 2 | 1 | 5 |
| Multiple | 0 | 1 | 0 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There is not a plan to make IPD available.
Ran from Jun 2020 to primary completion in Feb 2021, 8 months.
Results were first posted in Feb 2022, 11 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 8 months is close to that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir
Ridgeback Biotherapeutics, LP